Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2104-2120

  Claassens, Lily ^a,b,c,d,e   Van Meerbeeck, Jan ^a,b,c,d,e   Coens, Corneel ^a,b,c,d,e   Quinten, Chantal ^a,b,c,d,e   Ghislain, Irina ^a,b,c,d,e   Sloan, Elizabeth K ^a,b,c,d,e   Wang, Xin Shelly ^a,b,c,d,e   Velikova, Galina ^a,b,c,d,e   Bottomley, Andrew ^a,b,c,d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c EORTC DATA CENTER   (Belgium)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; SRL 172; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ADULT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79957520182     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3683     Document Type: Review

References (87)

1. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide-IARC CancerBase No. 10. Lyon, France, International Agency for Research on Cancer, 2010. http://globocan.iarc.fr
2. Devesa SS, Bray F, Vizcaino AP, et al: International lung cancer trends by histologic type: Male: female differences diminishing and adenocarcinoma rising. Int J Cancer 117:294-299, 2005 (Pubitemid 41379403)
3. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA, American Cancer Society, 2008
4. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two metaanalyses of individual patient data. Lancet 375:1267-1277, 2010
5. Triano LR, Deshpande H, Gettinger SN: Management of patients with advanced non-small cell lung cancer: Current and emerging options. Drugs 70:167-179, 2010
6. Ricciardi S, Tomao S, de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28-35, 2009
7. Patrick DL, Burke LB, Powers JH, et al: Patientreported outcomes to support medical product labeling claims: FDA perspective. Value Health 2:215-237, 2007
8. Efficace F, Bottomley A, Osoba D, et al: Beyond the development of health-related quality of life (HRQOL) measures: A checklist for evaluation of HRQOL outcomes in cancer clinical trials-Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21:3502-3511, 2003 (Pubitemid 46594084)
9. Efficace F, Bottomley A, Vanvoorden V, et al: Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. Eur J Cancer 40:187-197, 2004 (Pubitemid 38077020)
10. Efficace F, Osoba D, Gotay C, et al: Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18:775-781, 2007 (Pubitemid 46523284)
11. Kvam AK, Fayers P, Wisloff F: What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 84:345-353, 2010
12. D'Addario G, Früh M, Reck M, et al: Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116-v119, 2010 (suppl 5)
13. Bottomley A, Efficace F, Thomas R, et al: Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials. J Clin Oncol 21:2982-2992, 2003 (Pubitemid 46621851)
14. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al: Clinical-benefit response in advanced nonsmall cell lung cancer: A randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221-1230, 2001 (Pubitemid 32994749)
15. Vansteenkiste J, Vandebroek J, Nackaerts K, et al: Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: Detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 40: 191-199, 2003 (Pubitemid 36438720)
16. Falk SJ, Girling DJ, White RJ, et al: Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: Results of a randomized controlled trial. BMJ 325:465, 2002
17. Souquet PJ, Tan EH, Pereira RJ, et al:GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbineifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 13:1853-1861, 2002 (Pubitemid 36040773)
18. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003 (Pubitemid 36395256)
19. Gridelli C, Gallo C, Frances A, et al: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025-3034, 2003 (Pubitemid 46606281)
20. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003 (Pubitemid 46606280)
21. Belani CP, Pereira JR, von Pawel, et al: Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life: A randomized controlled trial. Lung Cancer 53:231-239, 2006 (Pubitemid 44043122)
22. Wachters FM, Van Putten JW, Kramer H, et al: First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: A phase III trial. Br J Cancer 89:1192-1199, 2003 (Pubitemid 37363401)
23. Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917, 2003 (Pubitemid 46606203)
24. Paccagnella A, Favaretto A, Oniga F, et al: Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: A multicenter, randomized phase III trial. Lung Cancer 43:83-91, 2004 (Pubitemid 38096297)
25. Kubota K, Watanabe K, Kunitoh H, et al: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV nonsmall-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261, 2004 (Pubitemid 41095089)
26. Groen HJ, van der Leest AH, Fokkema E, et al: Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: A multicenter phase III study. Ann Oncol 15:427-432, 2004 (Pubitemid 38444545)
27. O'Brien ME, Anderson H, Kaukel E, et al: SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol 15:906-914, 2004 (Pubitemid 39004346)
28. Laack E, Dickgreber N, Müller T, et al: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348-2356, 2004 (Pubitemid 41115391)
29. Stathopoulos GP, Veslemes M, Georgatou N, et al: Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced nonsmall-cell lung cancer: A randomized phase III trial. Ann Oncol 15:1048-1055, 2004 (Pubitemid 39089781)
30. Spiro SG, Rudd RM, Souhami RL, et al: Chemotherapy versus supportive care in advanced nonsmall cell lung cancer: Improved survival without detriment to quality of life. Thorax 59:828-836, 2004 (Pubitemid 39389621)
31. Brown S, Thorpe H, Napp V, et al: Closeness to death and quality of life in advanced lung cancer patients. Clin Oncol (R Coll Radiol) 19:341-348, 2007 (Pubitemid 46760596)
32. Lilenbaum RC, Chen CS, Chidiac T, et al: Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97-101, 2005 (Pubitemid 40124485)
33. Rudd RM, Gower NH, Spiro SG, et al: Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142-153, 2005 (Pubitemid 41702633)
34. Baka S, Ashcroft L, Anderson H, et al: Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136-2144, 2005 (Pubitemid 46218705)
35. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-smallcell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005 (Pubitemid 46218706)
36. Sarna L, Swann S, Langer C, et al: Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72:1378-1384, 2008
37. Movsas B, Moughan J, Sarna L, et al: Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. J Clin Oncol 27:5816-5822, 2009
38. Leighl NB, Paz-Ares L, Douillard JY, et al: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 23:2831-2839, 2005 (Pubitemid 46179474)
39. Pujol JL, Breton JL, Gervais R, et al: Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: A phase III study addressing the case for cisplatin. Ann Oncol 16:602-610, 2005 (Pubitemid 40613327)
40. Sundstrøm S, Bremnes R, Brunsvig P, et al: Immediate or delayed radiotherapy in advanced nonsmall cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol 75: 141-148, 2005 (Pubitemid 40805242)
41. Sundstrøm S, Bremnes R, Aasebø U, et al: Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial. J Clin Oncol 22:801-810, 2004 (Pubitemid 41103591)
42. Georgoulias V, Ardavanis A, Tsiafaki X, et al: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 23:2937-2945, 2005 (Pubitemid 46224112)
43. Belani CP, Lee JS, Socinski MA, et al: Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16:1069-1075, 2005 (Pubitemid 41418307)
44. Sederholm C, Hillerdal G, Lamberg K, et al: Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23:8380-8388, 2005
45. Socinski MA, Ivanova A, Bakri K, et al: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17:104-109, 2006 (Pubitemid 43033848)
46. Booton R, Lorigan P, Anderson H, et al: A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: A randomized multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 17:1111-1119, 2006 (Pubitemid 43985247)
47. Kudoh S, Takeda K, Nakagawa K, et al: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24: 3657-3663, 2006 (Pubitemid 46630541)
48. von Plessen C, Berman B, Andresen O, et al: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966-973, 2006 (Pubitemid 44606820)
49. Manegold C, Koschel G, Hruska D, et al: Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 8:245-251, 2007 (Pubitemid 46333569)
50. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323, 2007 (Pubitemid 46323100)
51. Gauthier I, Ding K, Winton T, et al: Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience. Lung Cancer 55:357-363, 2007 (Pubitemid 46329181)
52. Bezjak A, Lee CW, Ding K, et al: Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10. J Clin Oncol 26:5052-5059, 2008
53. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005 (Pubitemid 41007845)
54. Crawford J, Robert F, Perry MC, et al: A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2:210-220, 2007 (Pubitemid 47181326)
55. Leong SS, Toh CK, Lim WT, et al: A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2:230-236, 2007 (Pubitemid 47181328)
56. Lilenbaum R, Rubin M, Samuel J, et al: A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2:306-311, 2007 (Pubitemid 47181713)
57. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
58. Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced nonsmall-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512, 2007 (Pubitemid 46805905)
59. Gilligan D, Nicolson M, Smith I, et al: Preoperative chemotherapy in patients with respectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet 369:1929-1937, 2007 (Pubitemid 46874559)
60. Helbekkmo N, Sundstrøm SH, Aasebø U, et al: Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97:283-289, 2007 (Pubitemid 47196742)
61. Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinumbased chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007
62. Georgoulias V, Androulakis N, Kotsakis A, et al: Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced nonsmall cell lung cancer: A randomized, multicenter phase III trial. Lung Cancer 59:57-63, 2008
63. Lilenbaum R, Axelrod R, Thomas S, et al: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008 (Pubitemid 351398077)
64. Johnson EA, Marks RS, Mandrekar SJ, et al: Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 60:200-207, 2008 (Pubitemid 351609147)
65. Yang P, Mandrekar SJ, Hillman SH, et al: Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: An NCCTG-97-24-51 based study. J Thorac Oncol 4:479-485, 2009
66. Crinò L, Cappuzzo F, Zatloukal P, et al: Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): Randomized, phase II study. J Clin Oncol 26:4253-4260, 2008
67. Gebbia V, Galetta D, Lorusso V, et al: Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: A prospective randomized phase III trial of the G.O.C.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 61:369-377, 2008
68. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
69. Nyman J, Friesland S, Hallqvist A, et al: How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 65:62-67, 2009
70. Grønberg BH, Bremnes RM, Fløtten O, et al: Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-3224, 2009
71. Zwitter M, Kovac V, Smrdel U, et al: Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced nonsmall cell lung cancer: A randomized phase II clinical trial. J Thorac Oncol 4:1148-1155, 2009
72. Lee SM, Rudd R, Woll PJ, et al: Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:5248-5254, 2009
73. Takeda K, Hilda T, Sato T, et al: Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28:753-760, 2010
74. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
75. Zwitter M, Kovac V, Rajer M, et al: Two schedules of chemotherapy for patients with nonsmall cell lung cancer in poor performance status: A phase II randomized trial. Anticancer Drugs 21:662-668, 2010
76. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
77. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635-642, 1994 (Pubitemid 24164250)
78. Hollen PJ, Gralla RJ, Kris RG, et al: Quality of life during clinical trials: Conceptual model for the lung cancer symptom score (LCSS). Support Care Cancer 2:213-222, 1994
79. Hollen PJ, Gralla RJ, Kris MG, et al: Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73:2087-2098, 1994 (Pubitemid 24107963)
80. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993 (Pubitemid 23071057)
81. de Haes JCJM, van Knipperberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist. Br J Cancer 62:1034-1038, 1990
82. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999 (Pubitemid 29115600)
83. Brooks R: EuroQol: The current state of play. Health Policy 37:53-72, 1996 (Pubitemid 26191458)
84. Locke DEC, Decker PA, Sloan JA, et al: Validation of single-item Linear Analog Scale Assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage 34:628-638, 2007 (Pubitemid 350161248)
85. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in healthrelated quality-of-life scores. J Clin Oncol 16:139-144, 1998 (Pubitemid 28041591)
86. Hilbrich L, Sleight P: Progress and problems for randomized clinical trials: From streptomycin to the era of megatrials. Eur Heart J 27:2158-2164, 2006 (Pubitemid 44412828)
87. US Department of Health and Human Services Food and Drug Administration: Guidance for industry: Patient-reported outcome measures-Use in medical product development to support labeling claims. 2009. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf